
|Articles|February 1, 2004
Filler era offers new options, challenges
Waikoloa, Hawaii - The U.S. Food and Drug Administration's recent approval of the cosmetic dermal filler Restylane (Medicis) indicates the beginning of a new phase for dermatologists due to the enhanced benefits it offers patients, according to Mark G. Rubin, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Phase 2 Nemolizumab Trial Opens for CPUO
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















